# EDGAR Filing Document

**Accession Number:** 0001730430
**File Stem:** 0001415889-25-021941
**Filing Date:** 2025-8
**Character Count:** 8724
**Document Hash:** 05570b67e935481bcb287db1d1fa0f87
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-021941.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001415889-25-021941

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250812

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Malley Thomas
- **CENTRAL INDEX KEY:** 0001403322

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38492
- **FILM NUMBER:** 251220620

**MAIL ADDRESS:**
- **STREET 1:** C/O KINIKSA PHARMACEUTICALS, LTD.
- **STREET 2:** CLARENDON HOUSE, 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kiniksa Pharmaceuticals International, plc
- **CENTRAL INDEX KEY:** 0001730430
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 23 OLD BOND STREET, FLOOR 3
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WIS 4PZ
- **BUSINESS PHONE:** 7814319100

**MAIL ADDRESS:**
- **STREET 1:** 23 OLD BOND STREET, FLOOR 3
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WIS 4PZ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kiniksa Pharmaceuticals, Ltd.
- **DATE OF NAME CHANGE:** 20180205

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Malley Thomas<br><sub>(Last) (First) (Middle)</sub><br><br>23 OLD BOND STREET, THIRD FLOOR<br><sub>(Street)</sub><br>LONDON, X0 W1S 4PZ<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Kiniksa Pharmaceuticals International, plc [ KNSA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Ordinary Shares | 2025-08-12 |  | M |  | 21959 | A | $1.86 | 34505 | D |  |
| Class A Ordinary Shares | 2025-08-12 |  | M |  | 27448 | A | $3.80 | 61953 | D |  |
| Class A Ordinary Shares | 2025-08-12 |  | S |  | 49407 | D | 32.40<sup>(1)</sup> | 12546 | D |  |
| Class A Ordinary Shares | 2025-08-13 |  | M |  | 20129 | A | $10.36 | 32675 | D |  |
| Class A Ordinary Shares | 2025-08-13 |  | M |  | 30000 | A | $9.88 | 62675 | D |  |
| Class A Ordinary Shares | 2025-08-13 |  | S |  | 50129 | D | 33.32<sup>(2)</sup> | 12546 | D |  |
| Class A Ordinary Shares | 2025-08-14 |  | M |  | 18760 | A | $15.47 | 31306 | D |  |
| Class A Ordinary Shares | 2025-08-14 |  | M |  | 33237 | A | $14.33 | 64543 | D |  |
| Class A Ordinary Shares | 2025-08-14 |  | M |  | 26236 | A | $15.19 | 90779 | D |  |
| Class A Ordinary Shares | 2025-08-14 |  | S |  | 78233 | D | 33.09<sup>(3)</sup> | 12546 | D |  |
| Class A Ordinary Shares |  |  |  |  |  |  |  | 71967 | I | See footnote<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option | $1.86 | 2025-08-12 |  | M |  |  | 21959 | <sup>(5)</sup> | 2026-12-06 | Class A Ordinary Shares | 21959 | $0 | 0 | D |  |
| Share Option | $3.80 | 2025-08-12 |  | M |  |  | 27448 | <sup>(5)</sup> | 2027-06-28 | Class A Ordinary Shares | 27448 | $0 | 0 | D |  |
| Share Option | $10.36 | 2025-08-13 |  | M |  |  | 20129 | <sup>(5)</sup> | 2028-02-29 | Class A Ordinary Shares | 20129 | $0 | 0 | D |  |
| Share Option | $9.88 | 2025-08-13 |  | M |  |  | 30000 | <sup>(5)</sup> | 2032-06-28 | Class A Ordinary Shares | 30000 | $0 | 0 | D |  |
| Share Option | $15.47 | 2025-08-14 |  | M |  |  | 18760 | <sup>(5)</sup> | 2029-05-28 | Class A Ordinary Shares | 18760 | $0 | 0 | D |  |
| Share Option | $14.33 | 2025-08-14 |  | M |  |  | 33237 | <sup>(5)</sup> | 2031-06-28 | Class A Ordinary Shares | 33237 | $0 | 0 | D |  |
| Share Option | $15.19 | 2025-08-14 |  | M |  |  | 26236 | <sup>(5)</sup> | 2033-06-04 | Class A Ordinary Shares | 26236 | $0 | 0 | D |  |

---

### Footnotes:

(1) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.06 and $32.685. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

(2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.1301 and $33.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

(3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.82 and $33.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

(4) Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.

(5) The option is fully vested and exercisable.

**Signature:** /s/ Madelyn Zeylikman, Attorney-in-Fact  
**Date:** 2025-08-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**